The UK and US have agreed to a significant commercial pact that will maintain no tariffs on British medicine shipments going into the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the NHS. This commitment guarantees that import taxes on these vital products will stay at nothing for a duration of three years.
This deal follows recent threats to dramatically increase duties on branded drug imports, with increases floated as high as 100%.
"This deal with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement said.
Trade Importance
Pharmaceuticals are one of the Britain's biggest goods shipped to the US, which is easily the primary market for leading British pharmaceutical firms.
Trade data indicate that in the one-year period prior to September, the UK shipped drugs valued at over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This guarantee protects jobs, boosts capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key UK Commitments
The pact includes several key commitments from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be capped at 15%. Previously, rebates were more than 20%.
Industry Background
The deal comes amid a protracted dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
This friction were heightened by assertions that US consumers were paying a premium for the identical medicines than consumers in the other developed nations.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the last ten years.
